Single cell transcriptomics identifies stem cell-derived graft composition in a model of Parkinson's disease
- PMID: 32415072
- PMCID: PMC7229159
- DOI: 10.1038/s41467-020-16225-5
Single cell transcriptomics identifies stem cell-derived graft composition in a model of Parkinson's disease
Erratum in
-
Author Correction: Single cell transcriptomics identifies stem cell-derived graft composition in a model of Parkinson's disease.Nat Commun. 2020 Jul 15;11(1):3630. doi: 10.1038/s41467-020-17421-z. Nat Commun. 2020. PMID: 32669619 Free PMC article.
Abstract
Cell replacement is a long-standing and realistic goal for the treatment of Parkinson's disease (PD). Cells for transplantation can be obtained from fetal brain tissue or from stem cells. However, after transplantation, dopamine (DA) neurons are seen to be a minor component of grafts, and it has remained difficult to determine the identity of other cell types. Here, we report analysis by single-cell RNA sequencing (scRNA-seq) combined with comprehensive histological analyses to characterize intracerebral grafts from human embryonic stem cells (hESCs) and fetal tissue after functional maturation in a pre-clinical rat PD model. We show that neurons and astrocytes are major components in both fetal and stem cell-derived grafts. Additionally, we identify a cell type closely resembling a class of recently identified perivascular-like cells in stem cell-derived grafts. Thus, this study uncovers previously unknown cellular diversity in a clinically relevant cell replacement PD model.
Conflict of interest statement
M.P. is the owner of Parmar Cells AB and co-inventor of the U.S. patent application 15/093,927 owned by Biolamina AB and EP17181588 owned by Miltenyi Biotec. All other authors declare no competing interests.
Figures




Similar articles
-
Intrastriatal transplantation of stem cells from human exfoliated deciduous teeth reduces motor defects in Parkinsonian rats.Cytotherapy. 2018 May;20(5):670-686. doi: 10.1016/j.jcyt.2018.02.371. Epub 2018 Mar 22. Cytotherapy. 2018. PMID: 29576501
-
Human Clinical-Grade Parthenogenetic ESC-Derived Dopaminergic Neurons Recover Locomotive Defects of Nonhuman Primate Models of Parkinson's Disease.Stem Cell Reports. 2018 Jul 10;11(1):171-182. doi: 10.1016/j.stemcr.2018.05.010. Epub 2018 Jun 14. Stem Cell Reports. 2018. PMID: 29910127 Free PMC article.
-
Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson's disease.Cell Stem Cell. 2014 Nov 6;15(5):653-65. doi: 10.1016/j.stem.2014.09.017. Epub 2014 Nov 6. Cell Stem Cell. 2014. PMID: 25517469 Free PMC article.
-
Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease.J Mol Neurosci. 2004;24(3):353-86. doi: 10.1385/JMN:24:3:353. J Mol Neurosci. 2004. PMID: 15655260 Review.
-
Emerging restorative treatments for Parkinson's disease: manipulation and inducement of dopaminergic neurons from adult stem cells.CNS Neurol Disord Drug Targets. 2011 Jun;10(4):509-16. doi: 10.2174/187152711795563921. CNS Neurol Disord Drug Targets. 2011. PMID: 21495964 Review.
Cited by
-
Single-Cell Transcriptomics Uncovers Cellular Heterogeneity, Mechanisms, and Therapeutic Targets for Parkinson's Disease.Front Genet. 2022 May 4;13:686739. doi: 10.3389/fgene.2022.686739. eCollection 2022. Front Genet. 2022. PMID: 35601482 Free PMC article.
-
From cradle to grave: neurogenesis, neuroregeneration and neurodegeneration in Alzheimer's and Parkinson's diseases.Neural Regen Res. 2022 Dec;17(12):2606-2614. doi: 10.4103/1673-5374.336138. Neural Regen Res. 2022. PMID: 35662189 Free PMC article. Review.
-
Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy.Cell Stem Cell. 2023 Oct 5;30(10):1331-1350.e11. doi: 10.1016/j.stem.2023.08.013. Cell Stem Cell. 2023. PMID: 37802038 Free PMC article.
-
Bringing Advanced Therapies for Parkinson's Disease to the Clinic: The Scientist's Perspective.J Parkinsons Dis. 2021;11(s2):S135-S140. doi: 10.3233/JPD-212685. J Parkinsons Dis. 2021. PMID: 34250954 Free PMC article. Review.
-
Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges.Cells. 2020 Nov 20;9(11):2517. doi: 10.3390/cells9112517. Cells. 2020. PMID: 33233861 Free PMC article. Review.
References
-
- Cooper O, et al. Differentiation of human ES and Parkinson’s disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol. Cell Neurosci. 2010;45:258–266. doi: 10.1016/j.mcn.2010.06.017. - DOI - PMC - PubMed
-
- Barker RA, Parmar M, Studer L, Takahashi J. Human trials of stem cell-derived dopamine neurons for Parkinson’s disease: dawn of a new era. Stem Cell. 2017;21:569–573. - PubMed
-
- Barker, R. A. TRANSEURO consortium. Designing stem-cell-based dopamine cell replacement trials for Parkinson’s disease. Nat. Med.25, 1045–1053 (2019). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials